Navigation Links
The Female Health Company Schedules Third Quarter Conference Call for August 7, 2009
Date:7/31/2009

CHICAGO, July 31 /PRNewswire-FirstCall/ -- The Female Health Company (Nasdaq: FHCO) today announced that it will host an investor conference call to discuss its operating results for the third quarter and first nine months of FY2009 at 11:00 a.m. Eastern Time (EDT) on Friday, August 7, 2009. The Company expects to report its operating results earlier the same day.

Shareholders and other interested parties may participate in the conference call by dialing 800-860-2442 (international participants dial 412-858-4600) and asking to be connected to "The Female Health Company Conference Call", a few minutes before 11:00 a.m. EDT on August 7, 2009.

A replay of the call will be available one hour after the call through 5:00 p.m. EDT on August 21, 2009 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 432698.

About The Female Health Company

The Female Health Company (FHC), headquartered in Chicago, IL, is the maker of the FC Female Condom (FC1 and FC2), a revolutionary option offering women dual protection against both sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in February 1996 with the purchase of Chartex Resources Ltd., the holder of exclusive worldwide rights to FC1. The Company holds exclusive product and technology patents for FC1 in the United States, Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom, the People's Republic of China, South Korea and Japan. FC2 patents have been granted in Australia and South Africa and are pending in various other countries. FHC is the sole manufacturer and marketer of the FC1 and FC2 female condoms in the world. The Female Health Company and its partners currently market the Female Condom under FCFemale Condom(R), FC2 Female Condom(R), Reality(R), Femidom(R), Femy(R), and Care(R).

"Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's web site at http://www.femalehealth.com and http://www.femalecondom.org.

If you would like to be added to an e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com

    Contacts:  William R. Gargiulo, Jr.    231-526-1244
               Donna Felch, CFO            312-595-9123


'/>"/>
SOURCE The Female Health Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. UC Davis study highlights work-life issues of female surgeons
2. Female Surgeons Like What They Do, Survey Finds
3. Fortune Recognizes Female Health Company as One of Americas Fastest-Growing Small Companies
4. The Female Health Company Added to Russell 2000(R) Index
5. MassMutual Survey: Female Cancer Survivors Better Prepared Financially Than Other Women For Lifes Unexpected Events
6. The Female Health Company Switches to the NASDAQ Stock Market
7. Male or female? Coloring provides gender cues
8. The Female Health Company Reports 67% Increase in Second Quarter Earnings
9. Northshore Chicago Plastic Surgeon is the First Female President of the Aesthetic Surgery Education and Research Foundation (ASERF)
10. Video: New Survey Finds 97 Percent of Women Understand Weight Increases Heart Disease Risk - The Leading Cause of Female Death in the United States - Yet 55 Percent Remain Overweight
11. U.S. Market for Female Sterilization Devices to Grow 36% in 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... MadgeTech will be ... engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products sold ... monitoring solutions trusted by government agencies, including NASA. , In 2012, NASA strategically ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... Tampa, Fla. (PRWEB) , ... May 26, 2016 , ... ... Center (AHEC) to host a six-week smoking cessation class starting June 6 at their ... AHEC’s website, http://www.gnahec.org . , Additionally, the Lung Institute has created a free ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The MIAMI ... events featuring guest speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness ... Regenerative Medicine, and a member of the Institute for Functional Medicine. , He also ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Israel , May 27, 2016 ... an innovative biopharmaceutical company focused on late-stage drug ... Dexcel Pharma of pivotal batches required ... and Drug Administration (FDA). This follows Kitov,s ... Phase III trial successfully met its primary efficacy ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
Breaking Medicine Technology: